Skip to content

Cartomerge Versus NavX Fusion in Catheter Ablation of Atrial Fibrillation

Cartomerge Versus NavX Fusion in Catheter Ablation of Atrial Fibrillation

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01432743
Acronym
CAVERN
Enrollment
101
Registered
2011-09-13
Start date
2007-09-30
Completion date
2011-04-30
Last updated
2011-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

3D mapping, Image integration, Atrial fibrillation, Catheter Ablation

Brief summary

Comparison of Two Strategies for Catheter Ablation of Atrial Fibrillation - a comparison of ablation guided by Cartomerge and NavX Fusion. 3D mapping systems are widely used in catheter ablation of AF. Integration of a previously acquired image of the left atrium into the electroanatomical (EA) map offers several potential advantages, including visualisation of the complex anatomy of the left atrium, reduction of fluoroscopy time and improved results . The two most widely used systems are Cartomerge (Biosense Webster, etc) and NavX Fusion (SJM, etc). Although both systems have been independently validated, their clinical utility has not previously been directly compared in a randomised trial

Detailed description

Patients are randomised to either NavX Fusion or Cartomerge. They undergo a standard catheter ablation procedure and data is collected. Both systems are routinely used in our clinical practise. This is a comparison trial of 2 mapping technologies.

Interventions

PROCEDURENavX Fusion

Using NavX Fusion to guide catheter ablation

PROCEDURECartomerge

Guidance of catheter ablation using Cartomerge guidance

Sponsors

Barts & The London NHS Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Be at least 18 years of age * Be undergoing their first planned procedure for electrophysiology mapping and ablation in the left atrium of AF * Be willing and able to sign the study specific informed consent * Have a negative pregnancy test for female subjects of child bearing potential

Exclusion criteria

* Have a left ventricular ejection fraction (LVEF) of \<40% as evaluated by pre-procedure TTE * Have any contraindication or allergy to routine procedural medications or catheter materials * Have any condition for which the investigator feels it is unsafe for the subject to undergo an invasive electrophysiology procedure (EP) catheterisation * Be currently participating in another clinical research study * Have any condition for which the subject's life expectancy is less than twelve months

Design outcomes

Primary

MeasureTime frameDescription
AF recurrence6 monthsDocumentation of symptomatic arrhythmia or arrhythmia on a 7 day holter monitor at six-month follow-up

Secondary

MeasureTime frameDescription
Lesion distance from CT shellAt completion of catheter ablation procedure (distance at defined procedure endpoint) (between 0 - 6 hours after procedure start)Establish accuracy of lesion placement in relation to previously acquired CT shell to act as an indicator of guidance accuracy
Procedural time pointsAt start, during and end of inpatient catheter ablation procedure. (between 0 & 6 hours after start of ablation procedure)Measurement of all procedural time points during procedure, along with x-ray dose and screening times.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026